AA
MCID: ALP009
MIFTS: 62

Alopecia Areata (AA) malady

Categories: Rare diseases, Skin diseases, Genetic diseases, Immune diseases

Aliases & Classifications for Alopecia Areata

Aliases & Descriptions for Alopecia Areata:

Name: Alopecia Areata 12 50 24 29 52 42 14 69
Cazenave's Vitiligo 50 69
Jonston's Alopecia 50 69
Marginal Alopecia 50 69
Celsus' Vitiligo 50 69
Diffuse Alopecia 50 69
Alopecia Totalis 24 69
Alopecia Celsi 50 69
Circumscribed Alopecia 12
Alopecia Circumscripta 50
Alopecia Cicatrisata 50
Patchy Alopecia 50
Pseudopelade 69
Alopecia 69
Aa 50

Classifications:



External Ids:

Disease Ontology 12 DOID:986
ICD10 33 L63 L63.9 L66.0
ICD9CM 35 704.01
MeSH 42 D000506
UMLS 69 C0002171

Summaries for Alopecia Areata

NIH Rare Diseases : 50 alopecia areata (aa) is an autoimmune disease in which the immune system mistakenly attacks the hair follicles. in most cases, hair falls out in small, round patches on the scalp. although uncommon, hair loss can be more extensive in some people and affect other parts of the body. this condition can progress to complete loss of scalp hair (alopecia totalis) or total loss of all body hair (alopecia universalis). although the exact cause of aa is unknown, roughly 20% of affected people have a family member with alopecia, suggesting that genetic factors may contribute to the development of the condition. there is no cure or approved therapy for aa; however, some people find that medications approved for other purposes can help regrow hair. last updated: 11/23/2014

MalaCards based summary : Alopecia Areata, also known as cazenave's vitiligo, is related to hepatitis and autoimmune hemolytic anemia, and has symptoms including exanthema and pruritus. An important gene associated with Alopecia Areata is AIRE (Autoimmune Regulator), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Minoxidil and Finasteride have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and thyroid, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and hematopoietic system

Disease Ontology : 12 A hypersensitivity reaction type II disease resulting in the loss of hair on the scalp and elsewhere on the body initially causing bald spots.

Wikipedia : 71 Alopecia areata, also known as spot baldness, is an autoimmune disease in which hair is lost from some... more...

Related Diseases for Alopecia Areata

Diseases in the Alopecia Areata family:

Alopecia Areata 2 Alopecia Areata 1

Diseases related to Alopecia Areata via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 278)
id Related Disease Score Top Affiliating Genes
1 hepatitis 29.4 CTLA4 HLA-A IFNG IL2 TNF
2 autoimmune hemolytic anemia 29.3 CTLA4 FASLG IFNG IL2
3 rheumatoid arthritis 29.1 CTLA4 ICAM1 IFNG IL1A IL1RN IL2
4 diffuse alopecia areata 12.4
5 alopecia areata 1 12.3
6 amyloidosis aa 12.2
7 helsmoortel-van der aa syndrome 12.1
8 alopecia universalis 12.1
9 alopecia areata 2 12.1
10 alopecia totalis 11.6
11 adnp syndrome 11.4
12 alopecia 11.2
13 aplastic anemia 11.1
14 cutaneous telangiectasia and cancer syndrome, familial 11.0
15 renal nutcracker syndrome 11.0
16 immunodeficiency 7, tcr-alpha/beta deficient 11.0
17 bier spots 11.0
18 mental retardation, x-linked, syndromic, claes-jensen type 11.0
19 nail disorder, nonsyndromic congenital, 1 11.0
20 superior mesenteric artery syndrome 10.9
21 chondrodysplasia punctata, x-linked dominant 10.9
22 aarskog-scott syndrome 10.9
23 7q11.23 duplication syndrome 10.9
24 sveinsson choreoretinal atrophy 10.9
25 amyloidosis, hereditary, transthyretin-related 10.8
26 chromosome 7q11.23 duplication syndrome 10.8
27 adnp-related intellectual disability and autism spectrum disorder 10.7
28 amyloidosis 10.4
29 psoriasis 10.3
30 asymptomatic neurosyphilis 10.3 IFNG IL2RA
31 non-amyloid monoclonal immunoglobulin deposition disease 10.3 IL2RA PTPN22
32 stiff-person syndrome 10.3 IFNG IL1RN PTPN22
33 trichotillomania 10.3
34 autosomal dominant palmoplantar keratoderma and congenital alopecia 10.2
35 dermatitis 10.2
36 complement component 8 deficiency 10.2 AIRE CTLA4 PTPN22
37 ciliary discoordination, due to random ciliary orientation 10.2 IFNG IL1A IL2RA
38 senile reticular retinal degeneration 10.2 IFNG IL1RN TNF
39 pulpitis 10.2 CXCL10 IFNG TNF
40 t-cell prolymphocytic leukemia 10.2 IL2RA PTPN22 TNF
41 glucose intolerance 10.2 IFNG IL2RA TNF
42 thyroiditis 10.2
43 noonan-like syndrome with loose anagen hair 10.2 AIRE CTLA4
44 testicular leydig cell tumor 10.2 IL1A IL1RN IL2RA
45 anterior corneal pigmentation 10.2 HLA-A IL2RA PTPN22
46 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 10.2 AIRE IL2RA
47 hyperimmunoglobulin syndrome 10.2 CXCL10 IFNG TNF
48 status epilepticus 10.2 CXCL10 IFNG TNF
49 gonococcal endophthalmia 10.2 HLA-A IL1RN TNF
50 choanal atresia, bilateral 10.2 CXCL10 IL2RA TNF

Graphical network of the top 20 diseases related to Alopecia Areata:



Diseases related to Alopecia Areata

Symptoms & Phenotypes for Alopecia Areata

UMLS symptoms related to Alopecia Areata:


exanthema, pruritus

GenomeRNAi Phenotypes related to Alopecia Areata according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.72 IL2RA TNF GZMB ICAM1 IL1A IL2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.72 TNF FASLG GZMB ICAM1 IL1A IL2

MGI Mouse Phenotypes related to Alopecia Areata:

44 (show all 11)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.25 AIRE CTLA4 CXCL10 FASLG ICAM1 IFNG
2 cardiovascular system MP:0005385 10.24 CTLA4 CXCL10 FASLG ICAM1 IFNG IL1A
3 homeostasis/metabolism MP:0005376 10.22 ICAM1 IFNG IL1A IL1RN IL2 IL2RA
4 immune system MP:0005387 10.18 IL2RA MC2R PTPN22 TNF AIRE CTLA4
5 endocrine/exocrine gland MP:0005379 10.16 AIRE CTLA4 FASLG ICAM1 IFNG IL2
6 digestive/alimentary MP:0005381 10.13 AIRE CTLA4 FASLG ICAM1 IFNG IL2
7 mortality/aging MP:0010768 10.03 AIRE CTLA4 CXCL10 FASLG ICAM1 IFNG
8 liver/biliary system MP:0005370 9.87 PTPN22 TNF AIRE CTLA4 FASLG IFNG
9 neoplasm MP:0002006 9.7 AIRE FASLG ICAM1 IFNG IL1A IL2
10 respiratory system MP:0005388 9.56 IFNG IL2 IL2RA PTPN22 TNF AIRE
11 vision/eye MP:0005391 9.17 AIRE FASLG ICAM1 IFNG IL2 IL2RA

Drugs & Therapeutics for Alopecia Areata

Drugs for Alopecia Areata (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 360)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Minoxidil Approved Phase 4,Phase 3,Phase 1,Phase 2 38304-91-5 4201
2
Finasteride Approved Phase 4,Phase 3,Phase 1,Phase 2 98319-26-7 57363
3
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
4
Acitretin Approved Phase 4 55079-83-9 6437841 5284513
5
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
6
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
7
Doxorubicin Approved, Investigational Phase 4,Phase 2,Phase 3 23214-92-8 31703
8
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757 53477783
9
Spironolactone Approved Phase 4,Phase 2 1952-01-7, 52-01-7 5833
10
Drospirenone Approved Phase 4 67392-87-4 68873
11
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
12
Hydroxychloroquine Approved Phase 4 118-42-3 3652
13
Capsaicin Approved Phase 4 404-86-4 1548943
14
Imiquimod Approved, Investigational Phase 4,Phase 3 99011-02-6 57469
15
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
16
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 5460373 44475014
17
Bimatoprost Approved, Investigational Phase 4,Phase 2,Phase 1 155206-00-1 5311027
18
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
19
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
20
Manganese Approved, Nutraceutical Phase 4 7439-96-5 27854
21
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
22
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
23
Doxil Approved June 1999 Phase 4,Phase 2,Phase 3 31703
24 triamcinolone acetonide Phase 4,Phase 2
25 Prednisolone acetate Phase 4
26
Clobetasol Phase 4,Phase 3 25122-46-7 32798 5311051
27 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
28 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1
29 Gastrointestinal Agents Phase 4,Phase 2,Phase 1
30 Neuroprotective Agents Phase 4,Phase 2
31 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
32 Dermatologic Agents Phase 4,Phase 3,Phase 1,Phase 2
33 Trace Elements Phase 4,Phase 1,Phase 2
34 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
35 Triamcinolone diacetate Phase 4,Phase 2
36 Triamcinolone hexacetonide Phase 4,Phase 2
37 Hormones Phase 4,Phase 3,Phase 1,Phase 2
38 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
39 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
40 Vasodilator Agents Phase 4,Phase 3,Phase 1,Phase 2
41 Emollients Phase 4
42 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1,Phase 2
43 Anti-Asthmatic Agents Phase 4,Phase 1,Phase 2
44 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1
45 Estrogens Phase 4,Phase 3,Phase 2,Phase 1
46 Prednisolone hemisuccinate Phase 4
47 5-alpha Reductase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
48 Prednisolone phosphate Phase 4
49 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
50 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 308)
id Name Status NCT ID Phase
1 Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia Unknown status NCT01111981 Phase 4
2 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4
3 Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Unknown status NCT00224341 Phase 4
4 Aldara for the Treatment of Extensive Alopecia Areata Completed NCT00177021 Phase 4
5 Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5% Completed NCT00176943 Phase 4
6 Plaquenil for Alopecia Areata, Alopecia Totalis Completed NCT00176982 Phase 4
7 Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata Completed NCT02350023 Phase 4
8 Response of Topical Capsaicin in Alopecia Areata Completed NCT00176969 Phase 4
9 Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata Completed NCT01167946 Phase 4
10 Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children Completed NCT01023841 Phase 4
11 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4
12 Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses Completed NCT00774787 Phase 4
13 Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Completed NCT01511822 Phase 4
14 Myo-inositol Versus D-chiro-inositol in the Treatment of Polycystic Ovary Syndrome and Insulin Resistance: Evaluation of Clinical, Metabolic, Endocrine and Ultrasound Parameters Completed NCT01514942 Phase 4
15 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents Completed NCT01424644 Phase 4
16 Intralesional Steroids in the Treatment of Alopecia Areata Recruiting NCT01898806 Phase 4
17 Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia Active, not recruiting NCT02999737 Phase 4
18 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4
19 Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients Unknown status NCT01655108 Phase 3
20 Reflexology's Effect on Polycystic Ovary Syndrome: A Pilot Study Unknown status NCT00746148 Phase 3
21 Reflexology's Effect on Polycystic Ovary Syndrome (PCOS) Unknown status NCT00744510 Phase 3
22 Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous Unknown status NCT01222000 Phase 3
23 Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata Completed NCT00063076 Phase 2, Phase 3
24 A Trial of Clobetasol Propionate Versus Hydrocortisone in Children With Alopecia Areata Completed NCT01453686 Phase 3
25 The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis Completed NCT00997815 Phase 2, Phase 3
26 A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss Completed NCT00151515 Phase 3
27 Clinical Trial in Females With Female Pattern Hair Loss Completed NCT01145625 Phase 3
28 Clinical Trial in Females for Female Pattern Hair Loss Completed NCT01226459 Phase 3
29 Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia Completed NCT00958750 Phase 3
30 A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia Completed NCT00441116 Phase 3
31 A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3
32 Efficacy Study of Minoxidil Lotion Versus Combined Minoxidil and Finasteride Lotion to Treat Male Pattern Hair Loss Completed NCT01391156 Phase 3
33 Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia Completed NCT02014584 Phase 3
34 Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Completed NCT01231607 Phase 3
35 Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM) Completed NCT01590238 Phase 3
36 Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111) Completed NCT00396175 Phase 3
37 A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp Completed NCT02611804 Phase 3
38 Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis Completed NCT01686152 Phase 3
39 Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest Completed NCT02361216 Phase 3
40 Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs) Completed NCT00603798 Phase 3
41 Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs) Completed NCT00605176 Phase 3
42 Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Completed NCT00117767 Phase 3
43 Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Completed NCT00117754 Phase 3
44 A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Subjects With Actinic Keratoses Completed NCT02120898 Phase 3
45 Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis Completed NCT02616601 Phase 3
46 Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Completed NCT01426880 Phase 2, Phase 3
47 Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Completed NCT00916409 Phase 3
48 Assessment of the Transfer of Using Levonorgestrel Intrauterine System (LNG IUS) as a Contraceptive to Using it as Part of Hormone Replacement Therapy (HRT). Completed NCT00185458 Phase 3
49 Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer Completed NCT00486954 Phase 3
50 Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma Completed NCT00003350 Phase 3

Search NIH Clinical Center for Alopecia Areata

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: alopecia areata

Genetic Tests for Alopecia Areata

Genetic tests related to Alopecia Areata:

id Genetic test Affiliating Genes
1 Alopecia Areata 29 24

Anatomical Context for Alopecia Areata

MalaCards organs/tissues related to Alopecia Areata:

39
Skin, T Cells, Thyroid, Testes, Endothelial, Bone, Pituitary

Publications for Alopecia Areata

Articles related to Alopecia Areata:

(show top 50) (show all 751)
id Title Authors Year
1
Trichoscopic clues for diagnosis of alopecia areata and trichotillomania in Asians. ( 28074524 )
2017
2
Common phenotype and different non-HLA genes in Graves' disease and alopecia areata. ( 27810496 )
2017
3
Trichotillomania: a case report with clinical and dermatoscopic differential diagnosis with alopecia areata. ( 28225970 )
2017
4
Bilateral Half-Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata. ( 28044367 )
2017
5
Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients. ( 27816293 )
2017
6
Tofacitinib for the treatment of alopecia areata and variants in adolescents. ( 27816292 )
2017
7
Alopecia areata as a paraneoplastic syndrome of gastric cancer. ( 27990839 )
2017
8
Increased blood levels of NKG2D(+)CD4(+) TA cells in patients with alopecia areata. ( 27986136 )
2017
9
CURRENT AND FUTURE TREATMENTS OF ALOPECIA AREATA AND TRICHOTILLOMANIA IN CHILDREN. ( 27484130 )
2016
10
Alopecia Areata Sisaipho: Clinical and Therapeutic Approach in 13 Patients in Spain. ( 27601868 )
2016
11
Alopecia Areata as a Manifestation of Systemic Lymphoma: Report of Two Cases. ( 27843927 )
2016
12
Understanding autoimmunity of vitiligo and alopecia areata. ( 27191524 )
2016
13
Stem cell therapy as a novel therapeutic intervention for resistant cases of alopecia areata and androgenetic alopecia. ( 27553744 )
2016
14
Possible advantage of imiquimod and diphenylcyclopropenone combined treatment versus diphenylcyclopropenone alone: An observational study of nonresponder patients with alopecia areata. ( 27087586 )
2016
15
Alopecia areata (AA) and treatment with simvastatin/ezetimibe: Experience of 20 patients. ( 27085249 )
2016
16
Alopecia areata after denosumab treatment for osteoporosis. ( 27512722 )
2016
17
Phototherapy for alopecia areata. ( 27638443 )
2016
18
Multiple courses of pulse corticosteroid therapy for alopecia areata. ( 27095016 )
2016
19
Study of the comparative expression of CXCL9, CXCL10 and IFNI^ in vitiligo and alopecia areata patients. ( 27863059 )
2016
20
Beard alopecia areata: a multicentre review of 55 patients. ( 27503140 )
2016
21
Another guardian against alopecia areata? ( 27632964 )
2016
22
Cardiovascular risk in patients with alopecia areata (AA): A propensity-matched retrospective analysis. ( 27183846 )
2016
23
Alopecia areata totalis and universalis: a multicenter review of 132 patients in Spain. ( 27608049 )
2016
24
Alopecia areata in patients with inflammatory bowel disease: an overview. ( 27513834 )
2016
25
Distinguishing diffuse alopecia areata (AA) from pattern hair loss (PHL) using CD3(+) TA cells. ( 26851831 )
2016
26
Similarities of dermoscopic findings in alopecia areata between human and C3H/HeJ mouse. ( 27157926 )
2016
27
Alopecia areata incognita in Cronkhite-Canada Syndrome. ( 28029683 )
2016
28
Altered expression of intracellular Toll-like receptors in peripheral blood mononuclear cells from patients with alopecia areata. ( 27114923 )
2016
29
Alopecia areata, thyroiditis and vitiligo vulgaris in a Japanese patient with smoldering type adult T-cell leukemia/lymphoma. ( 27651025 )
2016
30
A novel therapeutic paradigm for patients with extensive alopecia areata. ( 27164008 )
2016
31
Measuring the impact of alopecia areata. ( 27632966 )
2016
32
Halo naevi, vitiligo and diffuse alopecia areata associated with tocilizumab therapy. ( 27516894 )
2016
33
Liquid Nitrogen Cryotherapy in Recalcitrant Alopecia Areata: A Study of 11 Patients. ( 27127370 )
2016
34
Hydroxychloroquine is ineffective in treatment of alopecia totalis and extensive alopecia areata: A case series of 8 patients. ( 27051848 )
2016
35
ULBP3: a marker for alopecia areata incognita. ( 27142445 )
2016
36
The Most Frequent Herbs Proposed by Iranian Traditional Medicine for Alopecia Areata. ( 27516698 )
2016
37
Assessment of vitamin D receptors in alopecia areata and androgenetic alopecia. ( 27151518 )
2016
38
The Frequency Distribution of Celiac Autoantibodies in Alopecia Areata. ( 27833723 )
2016
39
Trichoscopy as a useful method to differentiate tinea capitis from alopecia areata in children at Zagazig University Hospitals. ( 27654953 )
2016
40
Alopecia Areata-Part III: Prognosis and Treatment. ( 27871349 )
2016
41
Report of a Rare Case of Alopecia Areata Coexisting with Trichotillomania. ( 27127375 )
2016
42
Patient Perspectives: What is alopecia areata? ( 27882671 )
2016
43
Serial trichoscopy vs. modified hair pull test for monitoring the disease activity and treatment response of localized alopecia areata. ( 27557441 )
2016
44
Linear Alopecia Areata. ( 27625568 )
2016
45
Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers. ( 27119625 )
2016
46
Two Episodes of Simultaneous Identical Alopecia Areata in Identical Twins. ( 27127382 )
2016
47
Concentric Polycyclic Regrowth Pattern in Alopecia Areata. ( 27127376 )
2016
48
The Most Frequent Herbs Proposed by Iranian Traditional Medicine for Alopecia Areata. ( 27840535 )
2016
49
Immune-related alopecia (areata and universalis-type) in cancer patients receiving immune checkpoint inhibitors. ( 27943234 )
2016
50
Concurrence of Immune Thrombocytopenic Purpura and Alopecia Areata: A Rare Association. ( 27127385 )
2016

Variations for Alopecia Areata

Expression for Alopecia Areata

Search GEO for disease gene expression data for Alopecia Areata.

Pathways for Alopecia Areata

Pathways related to Alopecia Areata according to GeneCards Suite gene sharing:

(show all 49)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.99 CTLA4 CXCL10 FASLG HLA-A ICAM1 IFNG
2
Show member pathways
13.32 CXCL10 FASLG HLA-A ICAM1 IFNG IL1A
3
Show member pathways
13.28 CXCL10 FASLG IL1A IL2 IL2RA PTPN22
4
Show member pathways
12.87 CXCL10 FASLG IFNG IL2 TNF
5
Show member pathways
12.67 CXCL10 FASLG HLA-A ICAM1 IFNG IL1A
6
Show member pathways
12.6 CTLA4 FASLG GZMB HLA-A ICAM1 IFNG
7
Show member pathways
12.59 IFNG IL1A IL2 IL2RA TNF
8
Show member pathways
12.45 FASLG GZMB HLA-A ICAM1 IFNG IL2
9
Show member pathways
12.43 CTLA4 IFNG IL1A IL2 TNF
10 12.42 HLA-A ICAM1 IL2 IL2RA TNF
11
Show member pathways
12.31 ICAM1 IFNG IL2 TNF
12
Show member pathways
12.25 FASLG GZMB IL1A TNF
13
Show member pathways
12.18 CXCL10 FASLG IFNG TNF
14
Show member pathways
12.17 HLA-A IFNG IL1A IL2 TNF
15 12.09 ICAM1 IFNG IL1A TNF
16 12.01 CXCL10 ICAM1 IFNG IL1A IL2 TNF
17 12 IFNG IL2 IL2RA TNF
18 11.99 FASLG ICAM1 IL1A TNF
19
Show member pathways
11.96 FASLG GZMB HLA-A IFNG IL2 IL2RA
20 11.91 CXCL10 ICAM1 TNF
21
Show member pathways
11.91 IFNG IL2 TNF
22 11.89 CTLA4 ICAM1 IFNG IL1A TNF
23 11.87 ICAM1 IL1A TNF
24 11.86 IL1A IL2RA TNF
25 11.83 GZMB IFNG IL2 IL2RA TNF
26 11.82 CTLA4 CXCL10 FASLG GZMB IFNG IL1RN
27 11.78 ICAM1 IFNG IL2
28
Show member pathways
11.76 CTLA4 FASLG IFNG IL2 IL2RA TNF
29 11.75 CTLA4 ICAM1 IL2RA TNF
30 11.74 IFNG IL2 TNF
31
Show member pathways
11.69 ICAM1 IFNG IL1A IL2 TNF
32
Show member pathways
11.68 FASLG IL2 IL2RA
33 11.68 IFNG IL2 IL2RA
34 11.6 FASLG IFNG IL2 TNF
35 11.57 CXCL10 ICAM1 IL1A IL1RN TNF
36 11.54 ICAM1 IFNG TNF
37 11.53 FASLG IFNG IL1A TNF
38 11.52 IFNG IL2 TNF
39 11.51 IFNG IL2 IL2RA
40 11.47 FASLG ICAM1 IFNG
41 11.4 FASLG ICAM1 IFNG TNF
42 11.39 CXCL10 ICAM1 IFNG
43
Show member pathways
11.34 FASLG GZMB IFNG IL2 IL2RA TNF
44 11.33 IFNG IL2 IL2RA
45 11.33 IFNG IL1A IL2 TNF
46
Show member pathways
11.29 FASLG GZMB HLA-A IFNG IL2 IL2RA
47 11.25 IFNG IL2 IL2RA
48 11.23 CXCL10 FASLG IL1A IL2 TNF
49 10.91 ICAM1 TNF

GO Terms for Alopecia Areata

Cellular components related to Alopecia Areata according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 CXCL10 FASLG ICAM1 IFNG IL1A IL1RN
2 cell surface GO:0009986 9.55 FASLG HLA-A ICAM1 IL2RA TNF
3 external side of plasma membrane GO:0009897 9.17 CTLA4 CXCL10 FASLG ICAM1 IFNG IL2RA

Biological processes related to Alopecia Areata according to GeneCards Suite gene sharing:

(show all 31)
id Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.97 CTLA4 HLA-A IL2 IL2RA PTPN22
2 positive regulation of gene expression GO:0010628 9.95 IFNG IL1A PTPN22 TNF
3 positive regulation of apoptotic process GO:0043065 9.94 CTLA4 FASLG IFNG TNF
4 inflammatory response GO:0006954 9.88 CXCL10 IL1A IL1RN IL2RA TNF
5 regulation of immune response GO:0050776 9.86 HLA-A ICAM1 IFNG ULBP3
6 response to lipopolysaccharide GO:0032496 9.85 CXCL10 FASLG ICAM1 PTPN22
7 response to virus GO:0009615 9.81 CXCL10 IFNG TNF
8 interferon-gamma-mediated signaling pathway GO:0060333 9.76 HLA-A ICAM1 IFNG
9 positive regulation of T cell proliferation GO:0042102 9.75 IFNG IL2 IL2RA
10 humoral immune response GO:0006959 9.71 AIRE IFNG TNF
11 antigen processing and presentation GO:0019882 9.67 HLA-A IFNG ULBP3
12 natural killer cell mediated cytotoxicity GO:0042267 9.64 GZMB ULBP3
13 response to copper ion GO:0046688 9.63 ICAM1 IL1A
14 positive regulation of nitric oxide biosynthetic process GO:0045429 9.63 ICAM1 IFNG TNF
15 negative regulation of growth of symbiont in host GO:0044130 9.62 IFNG TNF
16 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.62 IFNG TNF
17 negative regulation of immune response GO:0050777 9.61 CTLA4 IL2RA
18 extrinsic apoptotic signaling pathway GO:0097191 9.61 FASLG IFNG TNF
19 positive regulation of chemokine biosynthetic process GO:0045080 9.6 IFNG TNF
20 positive regulation of isotype switching to IgG isotypes GO:0048304 9.59 IFNG IL2
21 necroptotic signaling pathway GO:0097527 9.52 FASLG TNF
22 negative regulation of lymphocyte proliferation GO:0050672 9.51 IL2 IL2RA
23 cellular response to lipopolysaccharide GO:0071222 9.46 CXCL10 ICAM1 IFNG TNF
24 regulation of T cell homeostatic proliferation GO:0046013 9.4 IL2 IL2RA
25 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.37 ICAM1 TNF
26 immune response GO:0006955 9.36 AIRE CTLA4 CXCL10 FASLG HLA-A IFNG
27 inflammatory cell apoptotic process GO:0006925 9.32 FASLG IFNG
28 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.26 IFNG TNF
29 positive regulation of vitamin D biosynthetic process GO:0060557 8.96 IFNG TNF
30 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.08 AIRE CXCL10 IFNG IL1A IL2 TNF
31 apoptotic process GO:0006915 10.04 FASLG GZMB IFNG IL1A IL2RA

Molecular functions related to Alopecia Areata according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.17 CXCL10 FASLG IFNG IL1A IL1RN IL2
2 interleukin-1 receptor binding GO:0005149 8.96 IL1A IL1RN

Sources for Alopecia Areata

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....